Brentuximab Vedotin Plus AVD Wins EU Approval for Previously Untreated CD30+ Stage III Hodgkin Lymphoma
October 19th 2023
The European Commission has approved brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult patients with previously untreated, CD30-positive, stage III Hodgkin lymphoma.